Stem Cell Therapeutics Announces Filing of Prospectus Supplement for Proceeds Up to $3.5 Million of Units

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE
SERVICES


Stem Cell Therapeutics Corp. ("SCT") (TSX VENTURE:SSS), a life sciences company
developing stem cell-related technologies, announced today that it has filed its
prospectus supplement dated March 11, 2013 in each of the Canadian provinces of
British Columbia, Alberta, Manitoba, Ontario and Nova Scotia to SCT's base shelf
prospectus of March 1, 2011 in respect of its previously announced offering of
securities. 


The offering consists of up to 14,000,000 units ("Units") which will be offered
at $0.25 each for gross proceeds of up to $3.5 million. Each Unit will be
comprised of one common share and one common share purchase warrants (the
"Warrants"). Each Warrant will entitle the holder to purchase an additional
common share for $0.40 for a period of 60 months following the closing of the
offering. Euro Pacific Canada Inc. is acting as the agent for the offering. 


Closing of the offering is expected to occur on or about March 15, 2013 and is
subject to customary conditions, including the approval of the TSX Venture
Exchange.


The purpose of the offering is to provide the resources necessary to conclude
the acquisition of Trillium Therapeutics Inc. by SCT, announced February 4th,
2013, and to trigger a condition precedent to permit the exercise of the option
by SCT to acquire the license to the Tigecycline intellectual property from the
University Health Network/MaRS Innovation, Toronto, announced November 7th,
2012. The assets expected to be acquired and licensed will conclude the initial
step of SCT's published corporate objectives for advancing the Corporation's
interests. 


This news release shall not constitute an offer to sell nor the solicitation of
an offer to buy, nor shall there be any sale of these securities in any
jurisdiction in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of any such
jurisdiction.


About Stem Cell Therapeutics: 

Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) develops stem cell-based
therapeutics through partnerships with research institutions and technology
transfer organizations. SCT's objectives include the sourcing and acquisition of
stem cell-related development opportunities, and securing capital for the
advancement of its licensed or acquired products. The Corporation's intended
corporate acquisitions and licensed acquisitions are positioning it principally
in the field of cancer stem cell therapeutic development. SCT is a member of the
20-member Centre for Commercialization of Regenerative Medicine consortium. For
more information, visit: www.stemcellthera.com


Forward Looking Statements

This press release may contain forward-looking statements, which reflect SCT's
current expectation regarding future events. These forward-looking statements
involve risks and uncertainties that may cause actual results, events or
developments to be materially different from any future results, events or
developments expressed or implied by such forward-looking statements. Such
factors include, but are not limited to, the closing of the offering; SCT's
ability to obtain financing in connection with the proposed transaction with
Trillium; uncertainties as to the timing and closing of the proposed transaction
with Trillium; the satisfaction of the conditions precedent to the completion of
the proposed transaction with Trillium; the satisfaction of the conditions
precedent to the exercise of the option to acquire a license to certain
technologies owned by University Health Network; the exercise of the option to
acquire a license to certain technologies owned by University Health Network;
the execution and delivery of a definitive license agreement with University
Health Network if SCT determines to exercise the University Health Network
option; the timing and closing of any Concurrent Private Placement; changing
market conditions; the successful and timely completion of pre-clinical and
clinical studies; the establishment of corporate alliances; the impact of
competitive products and pricing; new product development risks; uncertainties
related to the regulatory approval process or the ability to obtain drug product
in sufficient quantity or at standards acceptable to health regulatory
authorities to complete clinical trials or to meet commercial demand; and other
risks detailed from time to time in SCT's ongoing quarterly and annual
reporting, including in the base shelf prospectus dated March 1, 2011 and any
prospectus supplement. Except as required by applicable securities laws, SCT
undertakes no obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
Stem Cell Therapeutics Corp.
David Allan
Executive Chairman
[phone]
[e-mail]
www.StemCellThera.com